Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05620407 · ClinicalTrials.gov registry record · Phase 3

A Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-986165) Compared With Placebo in Participants With Active Systemic Lupus Erythematosus

A Phase 3 study of Systemic Lupus Erythematosus, sponsored by Bristol-Myers Squibb.

Active
Registry status
Phase 3
Development phase
513
Enrollment target
20
Study locations

NCT05620407: Active Phase 3 study of Systemic Lupus Erythematosus, sponsored by Bristol-Myers Squibb.

NCT05620407 is a Phase 3 study of Systemic Lupus Erythematosus that is active but no longer recruiting, run by Bristol-Myers Squibb. The registered enrollment target is 513 participants, above the 375-participant average among 99 other Systemic Lupus Erythematosus trials with a reported enrollment target (37% higher). The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05620407, a Phase 3 study of Systemic Lupus Erythematosus, is active but no longer recruiting, sponsored by Bristol-Myers Squibb.

ACTIVE NOT RECRUITING
Registry status
Phase 3
Development phase
513 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to evaluate the effectiveness and safety of deucravacitinib compared with placebo in an active moderate to severe Systemic Lupus Erythematosus (SLE) population.

Conditions Studied

Systemic Lupus Erythematosus

Interventions

  • OTHER Placebo
  • DRUG Deucravacitinib

Study Locations (20)

California

  • Local Institution - 0063 - La Jolla
  • Local Institution - 0241 - La Mesa
  • Local Institution - 0242 - San Diego
  • Local Institution - 0143 - San Leandro
  • Local Institution - 0147 - Santa Monica

Florida

  • Local Institution - 0213 - Clearwater
  • Local Institution - 0059 - Jacksonville
  • Local Institution - 0075 - Margate
  • Local Institution - 0007 - Oakland Park
  • Local Institution - 0239 - Plant City

Massachusetts

  • Local Institution - 0060 - Boston
  • Local Institution - 0056 - Boston
  • Local Institution - 0084 - Worcester

Georgia

  • Emory University School of Medicine- Grady Campus - Atlanta
  • Local Institution - 0137 - Marietta

Illinois

  • Local Institution - 0089 - Orland Park
  • Local Institution - 0041 - Skokie

Louisiana

  • Local Institution - 0231 - New Orleans

Michigan

  • Local Institution - 0152 - Grand Blanc

Minnesota

  • Local Institution - 0072 - Rochester

Trial Details

FieldValue
Enrollment Target 513 participants
Start Date 2023-01-12
Est. Completion 2028-11-13
Phase Phase 3
Bristol-Myers Squibb

1,025 total trials

What the registry record for NCT05620407 still lists

NCT05620407 is an interventional study that assigns participants to a tested intervention. The registered 513 participants enrollment target is mid-sized for trials with a published cap, above the 375-participant average among 99 other Systemic Lupus Erythematosus trials with a reported enrollment target (37% higher).

The record links to 1 condition, with Systemic Lupus Erythematosus appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT05620407 names 20 study sites across 8 states, led by California, Florida, Massachusetts.

Frequently Asked Questions

What is clinical trial NCT05620407 about?

NCT05620407 is a clinical study titled "A Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-986165) Compared With Placebo in Participants With Active Systemic Lupus Erythematosus". The purpose of this study is to evaluate the effectiveness and safety of deucravacitinib compared with placebo in an active moderate to severe Systemic Lupus Erythematosus (SLE) population.

What is the current status of trial NCT05620407?

This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 513 participants. The study started on 2023-01-12. Estimated completion is 2028-11-13.

What conditions does trial NCT05620407 study?

This clinical trial studies the following conditions: Systemic Lupus Erythematosus.

What interventions are being tested in trial NCT05620407?

The interventions under investigation include: Placebo (OTHER), Deucravacitinib (DRUG).

Who is sponsoring clinical trial NCT05620407?

This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05620407 being conducted?

This trial has 20 study locations across California, Florida, Georgia, Illinois, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Systemic Lupus Erythematosus

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05620407's enrollment target sits among peer trials

513 16th of 99 higher than 84 of 99 other Systemic Lupus Erythematosus trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Systemic Lupus Erythematosus trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05691244 · 514 participants · Phase 3

    Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke

  • NCT06585488 · 514 participants · Phase 1

    A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification

  • NCT06716606 · 514 participants · Phase 3

    A Study to Investigate the Long-term Safety and Efficacy of Belimumab in Adults With Interstitial Lung Disease (ILD) Associated With Systemic Sclerosis (SSc) and Other Connective Tissue Diseases (CTD) (BLISSconneCTD-OLE)

  • NCT05005403 · 512 participants · Phase 1

    Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of Azirkitug (ABBV-514) Alone or in Combination With Budigalimab or Bevacizumab

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT05620407, the US trial registry maintained by the National Library of Medicine. NCT05620407 (mid enrollment · wide site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.